Skip to content

Fertility-Sparing Treatment for Endometrial Cancer and Success Rates

Fertility-sparing treatment may allow selected patients with early endometrial cancer to postpone hysterectomy and attempt pregnancy. It does not guarantee that the cancer will respond, remain controlled or be followed by a live birth.

Those are three separate outcomes. A study can report a high initial response rate, a substantial recurrence rate and a much lower live birth rate without contradicting itself.

To understand the evidence, you need to know what researchers measured, when they measured it and which patients they counted. Those details matter more than a headline “success rate.”

Should Your Cancer Have Been Found Sooner?

Contact us today for a free consultation.

What Fertility-Sparing Treatment Involves

Endometrial cancer begins in the lining of the uterus. Surgery to remove the uterus remains the usual definitive treatment. Whether the ovaries should also be removed requires a separate assessment.

Fertility-sparing management generally uses progestin treatment while leaving the uterus in place. Approaches include oral medication, a levonorgestrel-releasing intrauterine device, or selected combinations. Some protocols include hysteroscopic removal of visible disease before hormone treatment.

Hysteroscopy uses a small camera passed through the cervix to examine the uterine cavity and obtain tissue.

The aim is to achieve a documented response, create an opportunity for pregnancy and maintain close cancer surveillance. Definitive surgery is generally recommended after childbearing or when conservative treatment is no longer appropriate.

Our overview of endometrial cancer treatment options explains the broader treatment setting.

Who May Be Considered for Fertility-Sparing Treatment?

Being young or wanting a pregnancy is not enough to establish eligibility.

The best-established candidates have grade 1 endometrioid cancer that appears confined to the endometrium, without invasion into the uterine muscle or evidence of disease elsewhere.

Assessment generally includes expert pathology review, appropriate imaging and evaluation of whether hormone treatment, pregnancy and repeated surveillance are suitable.

The 2023 ESGO/ESHRE/ESGE fertility-sparing guidelines emphasize careful selection and specialist review. Grade, tumor type, molecular findings and hereditary-risk considerations can change the discussion.

Imaging helps assess eligibility, but it cannot provide the same information as examining the uterus after surgery. That uncertainty is part of counseling.

What “Complete Response” Means

A complete response usually means that follow-up tissue sampling no longer identifies the disease specified by the study’s definition.

It does not prove that every abnormal cell has disappeared permanently. It also does not establish that pregnancy will occur.

Other outcomes need their own definitions:

  • Partial response means improvement without meeting the study’s complete-response criteria.

  • Persistent or stable disease means the disease remains without sufficient improvement.

  • Progression means worsening disease, such as higher-grade findings or newly identified invasion.

  • Recurrence means disease returns after a documented response.

A study reporting “response” may combine complete and partial responses. That number should not be described as a complete-remission rate.

A Prospective Trial Shows Why the Definition Matters

A phase II levonorgestrel-IUD trial published in 2021 included both atypical hyperplasia and grade 1 endometrioid cancer.

Among 47 evaluable patients, the reported 12-month overall response rate was 83%. However, that figure combined both diagnoses and included partial responses.

Within the cancer subgroup, eight patients had complete responses and two had partial responses. The reported cancer response rate of 66.7% therefore was not a complete-response rate.

This study illustrates why the endpoint and population must be checked before quoting a percentage.

How Often Does Cancer Respond or Return?

A 2026 systematic review of early-stage endometrial carcinoma included 76 studies and 2,507 patients. It reported a pooled complete-response rate of 74%, with a 95% confidence interval of 69–79%.

Among complete responders, the pooled recurrence estimate was 35%, with a confidence interval of 28–42%.

These figures summarize different regimens and study populations. They are not a personalized forecast, and the recurrence percentage applies to responders rather than everyone who began treatment.

The review also found substantial variation across studies. Its pooled numbers should therefore be discussed alongside the eligibility criteria, treatment method and follow-up relevant to an individual patient. PMC

Recurrence and Progression Are Different Safety Outcomes

Recurrence occurs after an initial response. Progression can occur without a complete response ever being achieved.

A study reporting few recurrences may still have patients who failed treatment or progressed before entering the recurrence analysis.

The definition of recurrence also matters. Some studies count a return of atypical hyperplasia; others focus on carcinoma.

Follow-up duration changes the opportunity to detect recurrence. A short series cannot establish that an initial response will remain durable over many years.

A complete assessment therefore considers response, persistence, progression, recurrence and the need for subsequent surgery.

Pregnancy Rates and Live Birth Rates Are Not Interchangeable

A pregnancy rate may refer to a positive pregnancy test, a clinically confirmed pregnancy or another defined endpoint.

A live birth rate answers a different question. Miscarriage and other pregnancy outcomes mean that the two percentages will not necessarily match.

The denominator is equally important.

One Hypothetical Result Can Produce Three Different Percentages

Consider an illustration, not a clinical study: 100 patients start treatment, 80 achieve complete response, 40 attempt pregnancy and 20 have at least one live birth.

Group used to calculate the rate

Calculation

Live birth rate

Everyone who started treatment

20 ÷ 100

20%

Everyone who achieved complete response

20 ÷ 80

25%

Patients who attempted pregnancy

20 ÷ 40

50%

All three percentages describe the same hypothetical outcomes.

A rate calculated only among patients who attempted pregnancy may help someone who has already responded and is ready to conceive. It does not describe the overall chance of live birth when starting cancer treatment.

IVF Results May Use Another Denominator

Fertility studies may report outcomes per patient, egg retrieval, treatment cycle or embryo transfer.

A live birth rate per embryo transfer cannot be directly compared with a rate calculated among everyone starting fertility-sparing cancer treatment.

Also check whether researchers counted patients with at least one live birth or the total number of babies born.

A 2026 analysis examining fertility-sparing outcomes and molecular classification highlighted this denominator problem and summarized reproductive outcomes narratively rather than pooling incompatible measures. pmc.ncbi.nlm.nih.gov

Monitoring Is Part of Treatment

Fertility-sparing management is active cancer treatment with repeated reassessment.

The 2023 European multidisciplinary guidelines recommend two consecutive biopsies showing complete response, separated by at least three months, to establish treatment success. Continued tissue assessment is recommended while awaiting pregnancy or definitive surgery.

They describe a usual response-assessment window of six to twelve months and call for multidisciplinary reassessment when there is no response at six months.

These timeframes do not authorize continued treatment despite progression or other concerning findings. The team should establish in advance what would trigger a change in management.

The American Cancer Society’s discussion of fertility-sparing treatment likewise emphasizes repeated sampling and the possibility that surgery will become necessary. pmc.ncbi.nlm.nih.gov

When Loss of Treatment Options May Support a Malpractice Claim

A New York malpractice claim requires evidence that care departed from accepted practice and that the departure caused injury.

For someone concerned about fertility, a review may examine whether appropriate earlier evaluation would likely have identified disease at a point when conservative treatment could reasonably have been considered.

That requires more than showing a delay followed by hysterectomy.

Relevant evidence includes symptom reports, bleeding history, treatment attempts, biopsy recommendations, pathology, imaging and the eventual treatment rationale. Qualified medical review must address whether the alleged delay changed the available options.

Our information about endometrial cancer malpractice claims explains the broader legal context.

New York Filing Deadlines

CPLR 214-a generally provides two years and six months to commence a medical malpractice action, subject to applicable rules, including qualifying continuous treatment.

For alleged negligent failure to diagnose cancer, its special discovery provision addresses knowledge of both the alleged negligence and resulting injury. The discovery branch includes a seven-year restriction measured from the alleged negligent act or omission.

Neither diagnosis nor hysterectomy automatically determines the deadline. Treatment-error allegations do not automatically receive the cancer failure-to-diagnose discovery rule.

Public defendants may involve additional notice and filing requirements. CPLR 203(g)(2) addresses their timing in qualifying cancer failure-to-diagnose claims.

New York Fertility Coverage Requires a Separate Inquiry

Fertility-sparing cancer treatment and fertility preservation services are related but different.

For example, Insurance Law 3216(i)(13)(C) requires covered individual policies to provide standard fertility preservation services when medical treatment may directly or indirectly cause infertility.

The New York Department of Financial Services’ coverage guidance explains the broader mandate for applicable state-regulated plans, including standard services such as collecting, freezing and storing eggs.

That mandate does not establish that every aspect of conservative cancer treatment, IVF or a particular fertility procedure is covered. Self-funded ERISA plans are not subject to this state mandate.

Request a written determination identifying the services covered, authorization requirements and applicable cost sharing.

Discuss a Possible Delay in Endometrial Cancer Diagnosis

If you believe abnormal bleeding or a recommended biopsy was not appropriately addressed, a legal review can examine what care was indicated and whether the delay caused additional harm.

Prepare the dates and records already available. You do not need a complete chart before making an inquiry.

Call Porter Law Group at 833-888-LATE or request a free endometrial cancer case evaluation.

Continue medical care and fertility counseling independently of any legal consultation.

This article is for informational and educational purposes only. It is not a substitute for medical advice from a qualified healthcare provider or legal advice based on your specific circumstances.

Attorney Advertising. Reading this article or contacting Porter Law Group does not create an attorney-client relationship.

Frequently Asked Questions

Does complete response mean my endometrial cancer is cured?

No. Complete response means that follow-up testing meets the specified criteria for no remaining disease in the sampled tissue. Cancer can still recur, and surveillance remains necessary. Ask how your team confirms response, how often further sampling is planned and which findings would make continued fertility-sparing management inappropriate.

Does a high response rate mean I have the same chance of a baby?

No. Cancer response, pregnancy and live birth are separate outcomes. Some patients do not respond, some never attempt pregnancy and some pregnancies do not result in live birth. A useful estimate must identify the patients counted and consider individual fertility factors as well as cancer control.

Can I assume fertility-sparing treatment is suitable because I am under 40?

No. Age alone does not establish eligibility. Selection depends on the cancer’s type, grade, apparent extent and other clinical findings, together with the suitability of treatment and surveillance. A gynecologic oncologist should review the diagnosis and explain whether the evidence supporting conservative management applies to your situation.

Will I still need a hysterectomy after having a child?

Definitive surgery is generally recommended after childbearing because recurrence remains possible. It may be needed earlier if treatment fails or disease worsens. Removal of the uterus and removal of the ovaries are separate decisions, so ask your team to explain the proposed operation and the reasons for each component.

Can a delayed diagnosis support a claim for losing fertility-sparing options?

Potentially, but the loss must be supported by medical evidence. A review must establish a departure from accepted care and explain how it changed the available options or caused other injury. Earlier diagnosis would not automatically have guaranteed conservative treatment, pregnancy or a live birth.

Free case evaluation

Talk With a New York Cancer Lawyer

If a delayed diagnosis changed your family's future, Porter Law Group can review what happened and explain your options.